| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Still's Disease, Adult-Onset | D016706 | 2 associated lipids |
| Leprosy, Borderline | D015439 | 3 associated lipids |
| Discitis | D015299 | 2 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Mycoplasma | D011019 | 6 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Periodontal Abscess | D010508 | 2 associated lipids |
| Sexually Transmitted Diseases, Bacterial | D015231 | 5 associated lipids |
| Conjunctivitis, Bacterial | D003234 | 3 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Owen RJ | Helicobacter pylori resists arrest. | 1999 | Gut | pmid:10075942 |
| Iwasaki A | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. | 1999 | Nippon Rinsho | pmid:10036949 |
| Habu Y et al. | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. | 1999 | Nippon Rinsho | pmid:10036950 |
| Shirai T et al. | [Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer]. | 1999 | Nippon Rinsho | pmid:10036951 |
| Yang JC et al. | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. | 1999 | J Microbiol Immunol Infect | pmid:11561564 |
| Nakagawa M et al. | [A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. | 1999 | Nippon Rinsho | pmid:10036952 |
| Kihira K et al. | [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. | 1999 | Nippon Rinsho | pmid:10036953 |
| Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
| Mach T and Zahradnik-Bilska J | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. | 1999 | Prz. Lek. | pmid:10575912 |
| Dionisio D et al. | Encephalitis caused directly by Mycoplasma pneumoniae. | 1999 | Scand. J. Infect. Dis. | pmid:10576133 |
| Huchon G | How to manage the low-risk patient with lower respiratory tract infection? | 1999 | Respiration | pmid:10577170 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Keiser P et al. | A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. | 1999 | Int J STD AIDS | pmid:10639059 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Yatsunami J et al. | Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. | 1999 | Cancer Lett. | pmid:10660084 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Catalano F et al. | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. | 1999 | Helicobacter | pmid:10469192 |
| Yoshida Y et al. | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10560737 |
| Boyanova L et al. | Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10459482 |
| Sendi PP et al. | Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. | 1999 | J Eval Clin Pract | pmid:10461580 |
| Kamada T et al. | Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. | 1999 | Helicobacter | pmid:10469195 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Härtig G et al. | [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. | 1999 | Psychiatr Prax | pmid:10457975 |
| Labenz J and Stolte M | [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. | 1999 | Z Gastroenterol | pmid:10458014 |
| Bazzoli F | My approach to Helicobacter pylori eradication. | 1999 | Eur J Gastroenterol Hepatol | pmid:10443911 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Hewitt RG et al. | Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. | 1999 | AIDS | pmid:10449290 |
| Enroth H et al. | Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. | 1999 | Clin. Infect. Dis. | pmid:10451171 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Debets-Ossenkopp YJ et al. | Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. | 1999 | J. Antimicrob. Chemother. | pmid:10350380 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Abbott GW et al. | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 | Cell | pmid:10219239 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Sato K and Tomioka H | [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo]. | 1999 | Kekkaku | pmid:10067057 |
| Schultz-Süchting F et al. | Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy. | 1999 | J. Pediatr. Gastroenterol. Nutr. | pmid:10067743 |
| Vásconez C et al. | Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. | 1999 | J. Hepatol. | pmid:10068106 |
| Fraser AG et al. | Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. | 1999 | Aust N Z J Med | pmid:10868529 |
| Yajima T et al. | Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. | 1999 | Chem. Pharm. Bull. | pmid:10071855 |
| Verbanck JJ et al. | Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. | 1999 Jan-Feb | Perit Dial Int | pmid:10201350 |
| Uygun A et al. | The effect of Helicobacter pylori eradication on duodenal gastric metaplasia. | 1999 Jul-Aug | J. Int. Med. Res. | pmid:10599027 |
| Gooderham MJ et al. | Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. | 1999 Jul-Aug | Ann Pharmacother | pmid:10466907 |
| Raderer M et al. | Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment. | 1999 Jul-Aug | Digestion | pmid:10394031 |
| Kyzekova J and Mour J | The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. | 1999 May-Jun | Hepatogastroenterology | pmid:10430396 |
| Ani AE et al. | Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. | 1999 Nov-Dec | Trans. R. Soc. Trop. Med. Hyg. | pmid:10717760 |
| Boxenbaum H | Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition. | 1999 Sep-Dec | J Pharm Pharm Sci | pmid:10953254 |
| Choudhury L et al. | Torsades de pointes due to drug interaction between disopyramide and clarithromycin. | 1999 Sep-Oct | Heart Dis | pmid:11720625 |
| Zgoulli S et al. | Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. | 1999 Sep-Oct | J Microencapsul | pmid:10499837 |
| Mikamo H et al. | Adequate macrolide treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. | 1999 Sep-Oct | Chemotherapy | pmid:10473928 |
| Galil K et al. | Abscesses due to mycobacterium abscessus linked to injection of unapproved alternative medication. | 1999 Sep-Oct | Emerging Infect. Dis. | pmid:10511524 |
| Zullo A et al. | A new highly effective short-term therapy schedule for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848654 |
| Moayyedi P et al. | The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848655 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Georgopoulos SD et al. | Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. | 2000 | Dig. Dis. Sci. | pmid:10695615 |
| Dore MP et al. | Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. | 2000 | Dig. Dis. Sci. | pmid:10695616 |
| Miwa H et al. | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. | 2000 | Dig. Dis. Sci. | pmid:10695617 |
| Shibuya N et al. | [Effect of clarithromycin on adhesion and infiltration of cancer cells]. | 2000 | Jpn J Antibiot | pmid:10756451 |
| Majima T et al. | [Administration of clarithromycin (CAM) to non-small cell lung cancer]. | 2000 | Jpn J Antibiot | pmid:10756452 |
| Bayerdörffer E | [The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol]. | 2000 | Z Gastroenterol | pmid:10689750 |
| Telenti A and Iseman M | Drug-resistant tuberculosis: what do we do now? | 2000 | Drugs | pmid:10730543 |
| Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
| Suzuki K et al. | Effect of proton pump inhibitor alone or in combination with clarithromycin on mycobacterial growth in human alveolar macrophages. | 2000 | FEMS Microbiol. Lett. | pmid:10612733 |
| Kelley MA et al. | Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. | 2000 | Clin. Infect. Dis. | pmid:11049784 |
| Komine M and Tamaki K | An open trial of oral macrolide treatment for psoriasis vulgaris. | 2000 | J. Dermatol. | pmid:10989574 |
| Cynamon MH et al. | Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. | 2000 | Antimicrob. Agents Chemother. | pmid:10991883 |
| Gasbarrini A et al. | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. | 2000 | Scand. J. Gastroenterol. | pmid:10766318 |
| Bojarski C et al. | Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. | 2000 | Z Gastroenterol | pmid:10768243 |
| Adamsson I et al. | Microbial ecology and treatment of Helicobacter pylori infections: review. | 2000 | J Chemother | pmid:10768510 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Mushiroda T et al. | The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. | 2000 | Drug Metab. Dispos. | pmid:10997945 |
| Jayasagar G et al. | Effect of clarithromycin on the pharmacokinetics of tolbutamide. | 2000 | Drug Metabol Drug Interact | pmid:11116754 |
| Aydin A and Isler M | Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. | 2000 | Clin Ther | pmid:11117661 |
| Ferrero M et al. | Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. | 2000 | Int. J. Antimicrob. Agents | pmid:11091043 |
| Yoshida H et al. | Reversal of intra-amniotic Chlamydia trachomatis antigen status. | 2000 | Gynecol. Obstet. Invest. | pmid:11093054 |
| Tateda K et al. | Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. | 2000 | J. Infect. Chemother. | pmid:11810524 |
| Kunishima H et al. | Evaluation of the activity of antimicrobial agents against Legionella pneumophila multiplying in a human monocytic cell line, THP-1, and an alveolar epithelial cell line, A549. | 2000 | J. Infect. Chemother. | pmid:11810567 |
| Vichev E et al. | [Gastroduodenitis and ulcers--statistical study for 1998]. | 2000 | Vutr Boles | pmid:11688321 |
| Gisbert JP et al. | Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971230 |
| Frevel M et al. | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971231 |
| Denis A et al. | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. | 2000 | Bioorg. Med. Chem. Lett. | pmid:10987440 |
| Moayyedi P et al. | Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. | 2000 | Helicobacter | pmid:11179985 |
| Hentschel E | [Treatment of Helicobacter pylori infections]. | 2000 | Acta Med. Austriaca | pmid:10989677 |
| Mégraud F et al. | Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. | 2000 | Helicobacter | pmid:11179987 |
| Bermudez LE et al. | Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10991834 |
| Sohn YT et al. | Polymorphism of clarithromycin. | 2000 | Arch. Pharm. Res. | pmid:10976587 |
| Bosne-David S et al. | Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. | 2000 | J. Antimicrob. Chemother. | pmid:10980165 |
| Huang AH et al. | Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. | 2000 | J. Formos. Med. Assoc. | pmid:11000734 |
| Shimizu T et al. | Case of intrafamilial Helicobacter pylori reinfection after successful eradication therapy. | 2000 | Pediatr. Infect. Dis. J. | pmid:11001123 |
| Bermejo F et al. | [Effects of Helicobacter pylori eradication on the recurrence of gastric ulcer during a 12-month follow up]. | 2000 | Med Clin (Barc) | pmid:11002456 |